Compare Citius Pharmaceuticals Inc (CTXR) vs Gigacloud Technology Inc (GCT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Gigacloud Technology Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while Gigacloud Technology Inc trades at $51.8 (market cap $1.84B). The key difference: Gigacloud Technology Inc is far larger — about 92× Citius Pharmaceuticals Inc's market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | GCT | |
|---|---|---|
Market Cap | $20.01M | $1.84B |
Sector | Health | Technology |
52-Week High | $1.82 | $53.25 |
52-Week Low | $0.48 | $25.44 |
Enterprise Value | $16.23M | $1.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
GigaCloud Technology (GCT) trades at $51.68, up 0.06% on the day, with a bullish technical outlook supported by moving averages and strong support at $50. The company reported Q2 2026 EPS of $1.16, beating estimates, and maintains a net income margin of 10.65%. Revenue growth is projected to rise from $1.29B in 2025 to $1.5B in 2026, while analyst sentiment is positive with a 66.7% buy rating.
The stock presents a compelling opportunity due to consistent earnings beats, robust profitability metrics like a 32.34% ROE, and attractive valuation with a P/E of 12.25. Key risks include reliance on B2B furniture logistics, competitive pressures, and potential margin compression from higher costs. Institutional confidence is bolstered by a $120M buyback program announced in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →
